key: cord-0940913-n8twee7s authors: Meyers, E.; Heytens, S.; Formukong, A.; Vercruysse, H.; De Sutter, A.; Geens, T.; Hofkens, K.; Janssens, H.; Nys, E.; Padalko, E.; Deschepper, E.; Cools, P. title: Comparison of dried blood spots and venous blood for the detection of SARS-CoV-2 antibodies in a population of nursing home residents date: 2021-05-18 journal: nan DOI: 10.1101/2021.05.17.21256410 sha: ab1d69b69888b25b2b8234c57c5ff95b2ddba92b doc_id: 940913 cord_uid: n8twee7s In the current SARS-CoV-2 pandemic, testing for SARS-CoV-2 specific antibodies is paramount to monitor immune responses in post-authorization vaccination and sero-epidemiology studies. However, large scale and iterative serological testing by venipuncture in older persons can be challenging. Capillary blood sampled using a finger prick and collected on protein saver cards, i.e. dried blood spots (DBS), has already proven to be a promising alternative. However, elderly persons have a reduced cutaneous microvasculature, which may affect DBS-based antibody testing. Therefore, we aimed to evaluate the performance of DBS for the detection of SARS-CoV-2 antibodies in nursing homes residents. We collected venous blood and paired Whatman and EUROIMMUN DBS from nursing home residents, and from staff as a reference population. Venous blood samples were analyzed for the presence of SARS-CoV-2 IgG antibodies using the Abbot chemiluminescent microparticle immunoassay (CMIA). DBS were analyzed by the EUROIMMUN enzyme-linked immuno sorbent assay (ELISA) for SARS-CoV-2 IgG antibodies. We performed a statistical assessment to optimize the ELISA cut-off value for the DBS using the Youden's J index. A total of 273 paired DBS-serum samples were analyzed, of which 129 were positive as assessed by the reference test. The sensitivities and specificities of DBS ranged from 95% to 97.1% and from 97.1% to 98.8%, respectively, depending on population (residents or staff) or DBS card type. These results demonstrate that DBS sampling is a valid alternative to venepuncture for the detection of SARS-CoV-2 antibodies in the elderly. In the current SARS-CoV-2 pandemic, testing for SARS-CoV-2 specific antibodies is 27 paramount to monitor immune responses in post-authorization vaccination and sero-28 epidemiology studies. However, large scale and iterative serological testing by venipuncture 29 in older persons can be challenging. Capillary blood sampled using a finger prick and collected 30 on protein saver cards, i.e., dried blood spots (DBS), has already proven to be a promising 31 alternative. However, elderly persons have a reduced cutaneous microvasculature, which may 32 affect DBS-based antibody testing. Therefore, we aimed to evaluate the performance of DBS 33 for the detection of SARS-CoV-2 antibodies in nursing homes residents. We collected venous blood and paired Whatman and EUROIMMUN DBS from nursing home 36 residents, and from staff as a reference population. Venous blood samples were analyzed for 37 the presence of SARS-CoV-2 IgG antibodies using the Abbot chemiluminescent microparticle 38 immunoassay (CMIA). DBS were analyzed by the EUROIMMUN enzyme-linked immuno 39 sorbent assay (ELISA) for SARS-CoV-2 IgG antibodies. We performed a statistical 40 assessment to optimize the ELISA cut-off value for the DBS using the Youden's J index. A total of 273 paired DBS-serum samples were analyzed, of which 129 were positive as 43 assessed by the reference test. The sensitivities and specificities of DBS ranged from 95.0% 44 to 97.1% and from 97.1% to 98.8%, respectively, depending on population (residents or staff) 45 or DBS card type. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Introduction 58 In the current severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic, 59 large-scale serological antibody studies are paramount to assess the true SARS-CoV-2 60 infection rate. Indeed, statistics on PCR-confirmed SARS-CoV-2 cases are far from ideal to estimate the true 62 proportion of the population that experienced a SARS-CoV-2 infection (1), as mildly affected 63 or asymptomatic individuals are often not tested and PCR-based testing only yields an 64 epidemiological snapshot. Furthermore, the recent implementation of newly developed SARS- CoV-2 vaccines creates an urgent need for population-based serological studies to monitor 66 antibody responses post-authorization. Protocols for SARS-CoV-2 antibody assays using 67 serum/plasma obtained by venipuncture are well established in a clinical setting. However, 68 venipuncture is invasive and can cause serious discomfort. Especially in the elderly, 69 venipuncture poses large challenges due to dehydration, loss of vein patency and low blood 70 pressure. Elderly may also suffer from arthritis, injury or stroke, impeding to hyperextend the 71 arms to survey for available veins. The use of venipuncture is further limited for wider 72 application in non-clinical settings due to the costs (for e.g., phlebotomists), logistical 73 constraints associated with collecting, processing, and transporting venous blood. Collecting capillary blood on protein saver cards after finger pricking using a lancet, the so-75 called dried blood spot (DBS), is a most valuable alternative as it is minimally invasive, can be 76 done at low cost, has the potential for self-sampling and is easy to ship and store. DBS are 77 increasingly applied as a minimally invasive alternative for infectious serology, especially in 78 community-and population-based epidemiology, including SARS-CoV-2 (2). However, the use 79 of DBS has not yet been validated for detection of SARS-CoV-2 antibodies in the elderly. Aging . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 4 is known to modify the cutaneous microvasculature and the structures of blood vessels, even We obtained approximately 5 ml of venous blood from each participant by venipuncture in 105 serum tubes using a 23G scalp vein set. Capillary blood was collected after briefly puncturing 106 the top edge of the distal phalanx of the middle or ring finger using 18G safety lancets 107 (Sarstedt, Numbrecht, Germany) onto Whatman protein saver cards (Whatman™, GE 108 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.17.21256410 doi: medRxiv preprint 5 Healthcare Sciences, Cardiff, UK). During sample collections, the protein saver card of 109 EUROIMMUN (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany) was 110 marketed and also evaluated on a subset of participants together with the Whatman protein 111 saver cards. For each protein saver card, a preprinted circle was filled until saturated (i.e., 112 blood was visible on the backside of the card). In order to avoid sampling bias, for half of the 113 participants (i.e., those with an even participant identification number), first a circle was filled 114 on the Whatman protein saver card, and then on the EUROIMMUN protein saver card, while 115 for the other half of the participants (those with an odd number), the opposite was done. Typically, an average of four blood drops were needed to saturate one circle. All blood 117 collections were done under aseptic conditions. DBS were obtained by allowing the capillary 118 blood to air-dry on the protein saver cards for one hour at room temperature. Serum tubes were transported to the Laboratory of Clinical Microbiology of the Ghent 120 University Hospital (Ghent, Belgium) within six hours after sample collection. Upon arrival, 121 serum tubes were centrifuged at 3000 g for 8 minutes, and tubes were stored at 4 °C. The antibodies. After thawing the sera and vortexing briefly, the Architect system analyzes the 134 samples automatically using a SARS-CoV-2 assay, a specific calibrator kit and a specific 135 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.17.21256410 doi: medRxiv preprint 6 control kit. We used an in-house validated cut-off index of 0.9 to classify sera as positive (≥0.9) 136 or negative (<0.9) for SARS-CoV-2 IgG antibodies. The sample size was calculated using the methodology described by Buderer (1996) , focusing 156 on the sensitivity (4). Here, we hypothesized sensitivity of DBS to be lower compared to sera 157 due to antibodies being affected by or remaining captured in the protein saver cards. Using an 158 anticipated sensitivity of 85%, an α level of 0.05 and a precision parameter (ε) of 0.10, we 159 needed a minimum of 49 positive sera, which were collected for both the residents and staff. The sensitivity and specificity of the DBS were calculated using the Abbott CMIA on sera from 161 venous blood as a reference test. The 95% confidence intervals (CI) were calculated using the 162 Wilson-Brown method (5). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.17.21256410 doi: medRxiv preprint 7 To determine the optimal cut-off value for the Whatman and EUROIMMUN DBS test, we 164 calculated Youden's J-index statistic, and the accuracy was calculated using the area under 165 the curve (AUC) of the receiver operating characteristic (ROC) curves. All analyses were performed using the statistical software GraphPad Prism 6 (GraphPad 167 Software Inc., San Diego, U.S.). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.17.21256410 doi: medRxiv preprint In four NHs, a total of 440 paired venous blood -Whatman DBS samples were obtained, of is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The optimal cut-off point for Whatman DBS was found to be 1.14, which is almost exactly the 240 value of 1.1 proposed by the manufacturer of the ELISA assay, and did not improve sensitivity 241 or specificity. The optimal cut-off point for EUROIMMUN DBS was found to be 1.02 and 242 applying this cutoff improved both sensitivity (from 95.1% to 96.4%) and specificity (from 97.1% 243 to 98.5%). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 13 In the present study, we evaluated the use of DBS for detection of SARS-CoV-2 antibodies in 253 residents and staff from nursing homes. To the best of our knowledge, we report the largest Several other studies in different populations, such as health care workers, key workers, 265 athletes and children have evaluated DBS sampling for SAR-CoV-2 antibody testing (6-14). In 266 these studies, similar test characteristics were reported with a sensitivity ranging from 89 up 267 to 100% and a specificity of 100% (7, 10, 11), or, reported a nearly perfect agreement in SARS- CoV-2 antibody detection between DBS samples and paired venous blood samples (6, 9, 12-269 14) . However, some studies were limited by the lack of serum serology as a reference test (7, where venous blood can be challenging to obtain. In comparison to serological rapid tests, 276 which can also be implemented in large-scale SARS-CoV-2 sero-epidemiological studies, DBS 277 offer higher sensitivity, specificity and the possibility to (semi-)quantitatively asses the antibody 278 response (15). Moreover, DBS have the advantage to collect and store the sample for multiple 279 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Our study was limited by the use of CMIA on venous blood samples that assessed 294 nucleocapsid antibodies, and not spike antibodies, which were detected by means of ELISA 295 in DBS. Conflicting results are available concerning the degree of persistence between 296 antibodies directed against the nucleocapsid and spike antigen, however, it is suggested that 297 IgG antibody levels directed against the nucleocapsid antigen wane more rapidly post-infection 298 than those against the spike antigen (16). Nevertheless, this should not impact the sensitivity 299 analysis in the current results, as nucleocapsid antibodies were detected as the reference. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.17.21256410 doi: medRxiv preprint 310 311 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Why is it difficult to accurately predict 313 the COVID-19 epidemic? Detection of SARS-CoV-2 antibodies using commercial assays and 317 seroconversion patterns in hospitalized patients The effect of aging on the cutaneous microvasculature Statistical methodology: I. Incorporating the prevalence of disease 321 into the sample size calculation for sensitivity and specificity Interval Estimation for a Binomial Proportion Dried Blood Spot as an Alternative 327 to Plasma/Serum for SARS-CoV-2 IgG Detection, an Opportunity to Be Sized Facilitate COVID-19 Surveillance Among Schoolchildren A serological 9 Development of a high-throughput SARS-CoV-2 antibody testing 341 pathway using dried blood spot specimens Sensitive Detection of SARS-CoV-2-345 Use of dried blood spot samples for SARS-CoV-2 348 antibody detection using the Roche Elecsys (R) high throughput immunoassay Can dried blood spots (DBS) contribute to conducting comprehensive SARS-CoV-2 352 antibody tests? The use of dried 355 blood spots for the serological evaluation of SARS-CoV-2 antibodies Evaluation of dried blood spots as alternative sampling material for serological 359 detection of anti-SARS-CoV-2 antibodies using established ELISAs The authors wish to thank all residents and their families, staff and management from the 309 nursing homes that participated in the study. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.17.21256410 doi: medRxiv preprint 365 GAE. Performance and operational feasibility of antigen and antibody rapid diagnostic 366 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 18, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021